Why clinical evidence alone isn’t enough

If you’re building a Health Tech startup, you already know how critical clinical validation is. Without it, your product won’t be trusted by clinicians, regulators, or patients. Grants often focus on funding trials and pilots precisely for this reason – it’s the foundation of credibility.

But here’s the catch: clinical validation doesn’t equal commercial traction. You could have peer-reviewed studies, glowing testimonials from doctors, and NHS pilot results – and still struggle to raise. Why? Because investors don’t just back science. They back businesses.

Understanding the difference between clinical validation and commercial traction is key to convincing investors you’re ready to scale.

Clinical validation: what it proves (and what it doesn’t)

Clinical validation proves your solution works in the real world. For Health Tech founders, that usually means:

• Successful pilots with hospitals or GP networks.
• Evidence of safety, accuracy, or patient outcomes.
• Regulatory milestones achieved (MHRA approval, CE/UKCA marking, data security compliance).

All of this matters enormously. Without it, you won’t get in the door with the NHS or private providers. But investors know plenty of startups that had strong validation and never made it to market.

Why? Because clinical validation alone doesn’t prove:

• Adoption willingness – Will the NHS or private providers actually buy at scale?
• Revenue potential – Can you price it sustainably?
• Scalability – Can it roll out beyond one hospital, region, or health system?

Investors will see clinical results as necessary but not sufficient.

Commercial traction: what investors really look for

Commercial traction is proof that your solution isn’t just effective, but sellable. Investors see traction as the shortcut to proving market readiness. They’re looking for signs like these:

• Paying customers – even if small scale or outside the NHS.
• Revenue growth, even if modest.
• Partnerships with insurers, corporates, or private healthcare.
• A pipeline of contracts, not just pilots.
• Evidence of repeat usage or renewals.

This is what turns investor heads. Commercial traction proves there’s a real business underneath the innovation.

Balancing both: the sweet spot investors want

The strongest Health Tech investment cases show both clinical validation and commercial traction. That doesn’t mean you need to be fully scaled before your next raise – but you do need to show you understand how to get there.

Practical ways to balance the two:

• Parallel pilots and commercial deals. While NHS validation takes time, private healthcare, insurance, or occupational health providers can deliver quicker contracts.
• Early adoption metrics. Even if you’re not revenue-heavy, show user engagement stats, clinician adoption rates, or patient outcomes in numbers investors can digest.
• Pricing experiments. Test different models during pilots to show how revenue could flow at scale.
• Conversion assumptions. Be explicit: “We expect 30% of pilot sites to convert into paying contracts within 12 months.”

Investors know Health Tech takes time. What they want to see is that you’re not stuck in research mode – you’re actively building the commercial side too.

The investor perspective: questions you need to answer

When pitching, expect investors to push on both sides:

On clinical validation:

• How rigorous are your results?
• What regulatory approvals are completed or pending?
• Do you have data security and privacy built in from day one?

On commercial traction:

• Who are your paying customers right now?
• How many pilots are converting into contracts?
• What does your pipeline look like for the next 12-24 months?
• How will you scale adoption without burning through cash?

If you can answer both sets confidently, you’re well on your way to being investor-ready.

Building the right financial story

The key is translating both validation and traction into your financial model. That means:

• Mapping compliance and clinical trial costs against timelines.
• Showing how long NHS procurement delays affect cashflow.
• Highlighting faster-moving revenue streams to offset long cycles.
• Demonstrating realistic unit economics: CAC, payback, lifetime value.

This is where many Health Tech founders underdeliver. They assume validation data speaks for itself. But investors need to see numbers, not just outcomes. A solid financial model proves you can connect the science to a sustainable business.

Investors back balance

Clinical validation gets you credibility. Commercial traction gets you funding. To raise successfully, you need both – or at least a clear path from one to the other.

At Standard Ledger UK, we help Health Tech founders bridge that gap by:

• Building financial models that capture both R&D spend and revenue potential.
• Crafting investor-ready decks that balance clinical and commercial narratives.
• Supporting fundraising strategy, from SEIS/EIS through to Series A.

Because the Health Tech startups that win funding aren’t just the ones with the strongest clinical evidence. They’re the ones that can prove they’re a real business too.